Financials

Discussions Technicals Seasonals

4157 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

TaiGen Biopharmaceuticals Holdings Ltd. engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes-related complications. Its products include treatment fordrug-resistant bacterial infections Nemonoxacin, stem cell mobilizer Burixafor, anti-influenza drug TG-1000 and anti-hapatitis C virus drug Furaprevir. The company was founded on September 15, 2005 and is headquartered in Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

4157 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company